These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 19355860)
1. Potential options to treat hypertriglyceridaemia. Viljoen A; Wierzbicki AS Curr Drug Targets; 2009 Apr; 10(4):356-62. PubMed ID: 19355860 [TBL] [Abstract][Full Text] [Related]
2. Treatment of hypertriglyceridemia: a review of current options. Vrablík M; Češka R Physiol Res; 2015; 64(Suppl 3):S331-40. PubMed ID: 26680666 [TBL] [Abstract][Full Text] [Related]
3. Demystifying the management of hypertriglyceridaemia. Watts GF; Ooi EM; Chan DC Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958 [TBL] [Abstract][Full Text] [Related]
4. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
5. Recommendations for severe hypertriglyceridemia treatment, are there new strategies? Filippatos TD; Elisaf MS Curr Vasc Pharmacol; 2014; 12(4):598-616. PubMed ID: 23627980 [TBL] [Abstract][Full Text] [Related]
6. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations. Hallén J; Sreeharan N Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):237-242. PubMed ID: 30060063 [TBL] [Abstract][Full Text] [Related]
7. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Breuer HW Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448 [TBL] [Abstract][Full Text] [Related]
8. Triglyceride as a risk factor for coronary artery disease. Gotto AM Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100 [TBL] [Abstract][Full Text] [Related]
9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemia and cardiovascular risk reduction. Jacobson TA; Miller M; Schaefer EJ Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898 [TBL] [Abstract][Full Text] [Related]
11. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. Kolovou GD; Watts GF; Mikhailidis DP; Pérez-Martínez P; Mora S; Bilianou H; Panotopoulos G; Katsiki N; Ooi TC; Lopez-Miranda J; Tybjærg-Hansen A; Tentolouris N; Nordestgaard BG Curr Vasc Pharmacol; 2019; 17(5):515-537. PubMed ID: 31309820 [TBL] [Abstract][Full Text] [Related]
12. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007 [TBL] [Abstract][Full Text] [Related]
13. Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis. He W; Lu N Hepatogastroenterology; 2015; 62(138):429-34. PubMed ID: 25916076 [TBL] [Abstract][Full Text] [Related]
14. Investigation and management of hypertriglyceridaemia. Ferns G; Keti V; Griffin B J Clin Pathol; 2008 Nov; 61(11):1174-83. PubMed ID: 18955574 [TBL] [Abstract][Full Text] [Related]